BRD4 and lymphoma: Pharmacological inhibition of the BET family proteins BRD2, BRD3, BRD4, and BRDt has emerged as a therapeutic approach to target MYC-dependent transcription [15, 16] because BRD4 regulates MYC and a number of other lymphoma-relevant oncogenes (BCL2, CDK4/6, and cyclin D1) [17–21].